Effect of probiotics at different intervention time on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Xinghui Wang, Lu Chen, Chunling Zhang, Qing Shi, Lei Zhu, Sisi Zhao, Zhiqin Luo, Yirun LongFrontiers in Endocrinology 2024 · DOI

Abstract

This systematic review and meta-analysis (PROSPERO ID: CRD42023483325) evaluates the efficacy of probiotic supplementation on glycemic control in patients with Type 2 Diabetes Mellitus (T2DM). Analyzing eight randomized controlled trials (RCTs), the study identifies a significant reduction in HbA1c, fasting insulin, and HOMA-IR. Notably, the duration of intervention plays a critical role: a 6–8 week window appears optimal for HbA1c reduction, while improvements in insulin sensitivity are sustained over longer periods.

Introduction

Type 2 Diabetes Mellitus (T2DM) remains a primary global health challenge, characterized by persistent hyperglycemia and systemic insulin resistance. While pharmacological interventions are standard, the role of the gut microbiome in metabolic regulation has emerged as a significant area of research. Probiotics—defined as live microorganisms providing health benefits to the host—have been proposed as a supplementary therapy to improve glucose metabolism. However, existing clinical literature presents conflicting results regarding their efficacy. This study hypothesizes that the duration of probiotic intervention is a key variable explaining these inconsistencies, seeking to identify the optimal timeframe for clinical benefits.

Methodology

Following PRISMA guidelines, a comprehensive search was conducted across PubMed, Embase, Web of Science, and the Cochrane Library for RCTs published through November 2023. Eligible studies compared probiotic intervention against a placebo in adult T2DM patients, reporting at least two primary glycemic markers: Fasting Blood Glucose (FBG), HbA1c, Insulin, HOMA-IR, or BMI.

Data synthesis was performed using RevMan 5.4, utilizing Mean Difference (MD) or Standardized Mean Difference (SMD) based on unit consistency. A random-effects model addressed high heterogeneity ($I^2 \ge 50\%$). A core component of the analysis was the subgrouping of results by intervention duration (6–8 weeks vs. 12–24 weeks).

Study Characteristics and Datasets

The final analysis included eight RCTs encompassing 507 participants (252 in probiotic groups; 255 in control groups). The studies spanned diverse geographic regions, including Iran, Ukraine, Brazil, Malaysia, and Greece, providing a broad demographic perspective.

Summary of clinical trial demographics and sample sizes across the eight included studies.

The probiotic formulations varied significantly, utilizing strains from Lactobacillus, Bifidobacterium, and Streptococcus genera, delivered in various formats such as capsules and powders.

Key Results and Meta-Analysis

The meta-analysis revealed statistically significant improvements in several key metabolic markers. Probiotic supplementation led to a mean reduction in HbA1c of -0.33% ($p = 0.01$). Fasting insulin levels showed a significant decrease (SMD = -0.48, $p = 0.0003$), as did insulin resistance measured via HOMA-IR (SMD = -1.36, $p = 0.005$). Conversely, changes in Fasting Blood Glucose (FBG) and BMI did not reach statistical significance ($p = 0.08$ and $p = 0.25$, respectively).

Detailed intervention protocols and the resulting delta (change) in glycemic markers for each study.

The Impact of Intervention Duration

Subgroup analysis provided the most critical insight: the "time window" effect. For HbA1c, significant improvements were only observed in the 6–8 week subgroup. In contrast, the benefits for fasting insulin and HOMA-IR were consistent across both short-term (6–8 weeks) and long-term (12–24 weeks) interventions. This suggests that while insulin sensitivity improvements are durable, the impact on long-term glucose markers like HbA1c may be most pronounced in an early "reset" phase.

Discussion and Limitations

The findings suggest that probiotics primarily function by enhancing insulin sensitivity rather than through direct glucose clearance. The lack of significant BMI reduction implies that these metabolic benefits are likely driven by biochemical pathways—such as reduced systemic inflammation or improved gut barrier integrity—rather than weight loss.

Several limitations affect the generalizability of these results. The total sample size (n=507) is relatively small, and high heterogeneity exists regarding probiotic strains and dosages. Furthermore, the exclusion of non-English/Chinese literature and "gray literature" may introduce bias. Future research should prioritize large-scale, multi-center RCTs with standardized protocols to confirm these time-dependent effects.

Conclusion

Probiotic supplementation offers a promising adjunctive therapy for T2DM, particularly for improving insulin sensitivity. Clinical application should consider the 6–8 week intervention window as a critical period for achieving significant reductions in HbA1c.

Summary updated

Abstract

https://www.crd.york.ac.uk/prospero, identifier CRD42023483325.
BibTeX
@inproceedings{wang2024effect,
  author = {Xinghui Wang and Lu Chen and Chunling Zhang and Qing Shi and Lei Zhu and Sisi Zhao and Zhiqin Luo and Yirun Long},
  title = {{Effect of probiotics at different intervention time on glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis}},
  booktitle = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1392306},
}
Figure